Fisher Asset Management LLC Sells 14,528 Shares of Medtronic PLC $MDT

Fisher Asset Management LLC trimmed its position in shares of Medtronic PLC (NYSE:MDT) by 6.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 225,001 shares of the medical technology company’s stock after selling 14,528 shares during the period. Fisher Asset Management LLC’s holdings in Medtronic were worth $21,614,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MDT. Lodestone Wealth Management LLC bought a new stake in Medtronic during the fourth quarter valued at about $27,000. Anfield Capital Management LLC boosted its stake in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Medtronic in the fourth quarter worth about $29,000. GoalVest Advisory LLC purchased a new stake in shares of Medtronic during the fourth quarter worth about $29,000. Finally, Valley Wealth Managers Inc. bought a new stake in Medtronic during the 3rd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on MDT shares. Weiss Ratings cut Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 21st. Robert W. Baird lifted their price objective on shares of Medtronic from $92.00 to $93.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. CICC Research assumed coverage on shares of Medtronic in a report on Friday, January 30th. They issued an “outperform” rating on the stock. UBS Group dropped their target price on shares of Medtronic from $104.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, April 22nd. Finally, Truist Financial cut their target price on shares of Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a research note on Wednesday, April 15th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $106.45.

Medtronic Stock Down 1.3%

NYSE MDT opened at $77.60 on Wednesday. The stock has a 50 day moving average price of $83.13 and a 200-day moving average price of $93.00. Medtronic PLC has a one year low of $74.40 and a one year high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. The company has a market capitalization of $99.63 billion, a P/E ratio of 21.62, a P/E/G ratio of 1.87 and a beta of 0.62.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Friday, March 27th were issued a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.7%. Medtronic’s payout ratio is 79.11%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).